Cargando…

Different therapeutic approaches on quality of life in patients with inflammatory bowel disease

BACKGROUND: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the im...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Junjie, Lin, Hui, Feng, Xu, Tang, Minyue, Shen, Jun, Ran, Zhihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271410/
https://www.ncbi.nlm.nih.gov/pubmed/25421821
http://dx.doi.org/10.1186/s12876-014-0199-5
_version_ 1782349600567328768
author Xu, Junjie
Lin, Hui
Feng, Xu
Tang, Minyue
Shen, Jun
Ran, Zhihua
author_facet Xu, Junjie
Lin, Hui
Feng, Xu
Tang, Minyue
Shen, Jun
Ran, Zhihua
author_sort Xu, Junjie
collection PubMed
description BACKGROUND: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated. METHODS: Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment. RESULTS: MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048). CONCLUSIONS: MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-014-0199-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4271410
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42714102014-12-20 Different therapeutic approaches on quality of life in patients with inflammatory bowel disease Xu, Junjie Lin, Hui Feng, Xu Tang, Minyue Shen, Jun Ran, Zhihua BMC Gastroenterol Research Article BACKGROUND: The chronic nature of inflammatory bowel disease leads to considerable impairment on the health related quality of life (HRQOL). The aims of the present study are to validate the mainland Chinese translation of the Inflammatory Bowel Disease Questionnaire (MCIBDQ), and to evaluate the impact of infliximab treatment on HRQOL in patients with IBD for the first time in China, as compared with other therapies of different levels. Furthermore, the impact of different medical therapies on marriage, employment and economic burden in IBD patients were also evaluated. METHODS: Consecutive patients who met inclusion/exclusion criteria were investigated with MCIBDQ, SF-36, disease activity index (DAI), marriage, employment and economic burden questionnaires before and after treatment. RESULTS: MCIBDQ showed significant reliability and validity both in CD and UC patients. The scores of total SF-36, total MCIBDQ and all domains were found significantly increased, while both DAI and health transition on general health scores were found significantly decreased after infliximab treatment (all P < 0.001). Scores of SF-36 and MCIBDQ increased significantly more in infliximab group than non-infliximab group (all P < 0.05). Infliximab treatment was suggested to significantly reduce the negative impact on love (P = 0.037), increase work time (P = 0.016) and ease economic burden (P = 0.048). CONCLUSIONS: MCIBDQ was demonstrated to be a reliable and valid scale applied in Chinese IBD patients. Infliximab treatment was found to significantly improve HRQOL in IBD patients in comparison with conventional treatments. Negative impact on marriage, employment, and economic status was found in patients with IBD. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12876-014-0199-5) contains supplementary material, which is available to authorized users. BioMed Central 2014-11-25 /pmc/articles/PMC4271410/ /pubmed/25421821 http://dx.doi.org/10.1186/s12876-014-0199-5 Text en © Xu et al.; licensee BioMed Central Ltd. 2014 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Xu, Junjie
Lin, Hui
Feng, Xu
Tang, Minyue
Shen, Jun
Ran, Zhihua
Different therapeutic approaches on quality of life in patients with inflammatory bowel disease
title Different therapeutic approaches on quality of life in patients with inflammatory bowel disease
title_full Different therapeutic approaches on quality of life in patients with inflammatory bowel disease
title_fullStr Different therapeutic approaches on quality of life in patients with inflammatory bowel disease
title_full_unstemmed Different therapeutic approaches on quality of life in patients with inflammatory bowel disease
title_short Different therapeutic approaches on quality of life in patients with inflammatory bowel disease
title_sort different therapeutic approaches on quality of life in patients with inflammatory bowel disease
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4271410/
https://www.ncbi.nlm.nih.gov/pubmed/25421821
http://dx.doi.org/10.1186/s12876-014-0199-5
work_keys_str_mv AT xujunjie differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease
AT linhui differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease
AT fengxu differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease
AT tangminyue differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease
AT shenjun differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease
AT ranzhihua differenttherapeuticapproachesonqualityoflifeinpatientswithinflammatoryboweldisease